Ally Bridge Group (NY) LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$43.4M2026 Q3+ $32.6M options (notional, not included)
Positions18
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.87.9%
What Changed This Quarter?
Top Holdings
DFTXCALL
Definium Therapeutics
20.0%
ABVXCALL
Abivax S.A.
16.3%
EWTX
Edgewise Therapeutics
9.9%
PMN
ProMIS Neurosciences
8.9%
NERV
Minerva Neurosciences
7.3%
AMLX
Amylyx Pharmaceuticals
7.0%
STTK
Shattuck Labs
5.6%
OBX
Obsidian Therapeutics
5.5%
New / Increased
6 new · 1 increased
AMLXNEW
Amylyx Pharmaceuticals
7.0%
STTKNEW
Shattuck Labs
5.6%
OBXNEW
Obsidian Therapeutics
5.5%
ALMSCALLNEW
Alumis
3.9%
CMPXCALLNEW
Compass Therapeutics
2.7%
EWTX
Edgewise Therapeutics
9.9%
+122.6%
Reduced / Exited
6 reduced · 13 sold out
ASMB
Assembly Biosciences
0.6%
-86.9%
NERV
Minerva Neurosciences
7.3%
-23.9%
CATX
Perspective Therapeutics
0.6%
-78.0%
IVA
Inventiva
1.1%
-64.2%
AVTX
Avalo Therapeutics
2.7%
-10.4%
TRAXEXIT
First Tracks Biotherapeutics
5.1%
AXSMEXIT
Axsome Therapeutics
3.6%
WHWKEXIT
Whitehawk Therapeutics
3.3%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.